Aggressive retinopathy of prematurity (A-ROP) represents a severe, rapidly progressive variant of retinopathy of prematurity (ROP) that is most observed in extremely premature, low-birth-weight infants and usually involves the posterior zones. Its occurrence in near-term infants with normal birth weight, involving Zone 3, is rare. This report dwells upon such a rare occurrence. This is a case of a male baby born at 37 weeks' gestation with a birth weight of 3,200 g. The baby required a neonatal ICU (NICU) admission for 13 days for respiratory distress and seizures. At a postmenstrual age of 40 weeks, fundus examination revealed A-ROP in both eyes in Zone 3. After parental counseling, bilateral intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy with bevacizumab (one-third adult dose, 0.4 mg/0.015 mL) was administered. The infant showed rapid regression of plus disease and hemorrhages. Subsequent follow-ups demonstrated continued improvement, with complete retinal maturation by six months. At the final follow-up, the child had a mature retina, an unremarkable anterior segment, and a refraction of +0.50 DS/−2.00 DC × 180° in both eyes. This case highlights a rare presentation of A-ROP involving Zone 3 in a near-term, normal birth-weight infant. The potential role of postnatal factors, including respiratory distress management, in the development of A-ROP outside traditional risk profiles. The prognosis is good if the condition is treated promptly and there is no further systemic deterioration.
Jain et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: